| Document |
Document Title |
|
WO/2023/023942A1 |
Provided are compounds of Formula I, compositions comprising the compound of Formula I, and methods of using the same, in treating diseases, disorders, or conditions mediated by the inhibition of hematopoietic progenitor kinase 1 (HPK1).
|
|
WO/2023/028238A1 |
The present invention provides compounds inhibiting eIF4E activity, and compositions and methods of using thereof.
|
|
WO/2023/027948A1 |
The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of JAK2 enzymes with the compounds and compositions of the disclosure. The present disclosure further rela...
|
|
WO/2023/025602A1 |
The invention relates to compounds of formula I I wherein the variables have the meanings as defined in the specification, to compositions com-prising them, to active compound combinations comprising them, and to their use for protecting...
|
|
WO/2023/025092A1 |
The present disclosure provides compounds of Formula I', compositions comprising the compound of Formula I', and methods of using the same, in treating diseases, disorders, or conditions mediated by the inhibition of certain kinases, suc...
|
|
WO/2023/020964A1 |
The present invention relates to substituted 1,2,4-thiadiazolyl nicotinamides of the general formula (I), salts or N-oxides thereof, where the radicals in the general formula (I) correspond to the definitions given in the description, an...
|
|
WO/2023/021012A1 |
Suggested are compositions comprising substituted azacycles on one hand and physiological cooling or warming agents, flavors and/or fragrances on the other for masking, enhancing and/or boosting flavors, improving soothing ability, and i...
|
|
WO/2023/020347A1 |
A pyrimidopyridine compound represented by the general formula (I), a preparation method therefor, a pharmaceutical composition containing same, and a use thereof as a KRAS -G12D inhibitor. The compound and the pharmaceutical composition...
|
|
WO/2023/020962A1 |
The present invention relates to substituted 1,2,4-thiadiazolyl nicotinamides of the general formula (I), salts or N-oxides thereof, where the radicals in the general formula (I) correspond to the definitions given in the description, an...
|
|
WO/2023/022417A1 |
Provided is a cyano group-substituted heteroaryl amine derivative which effectively absorbs high-energy external light source in the UV region to minimize damage to organic materials inside an organic electroluminescent device, thus cont...
|
|
WO/2023/023572A1 |
Provided are compounds having the structure of Formula One or Formula Two: Formula One, or Formula Two. Pesticidal compositions and their uses are disclosed. Also disclosed are methods of synthesis for compounds disclosed herein.
|
|
WO/2023/023242A1 |
Disclosed are compounds of Formula 1 including all geometric and stereoisomers, N- oxides, and salts thereof, wherein Q1, Q2 and J are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 an...
|
|
WO/2023/020523A1 |
A compound of Formula (I), (II) or (III), stereoisomer thereof, pharmaceutically acceptable salt thereof, pharmaceutically acceptable salt of the stereoisomer are disclosed.
|
|
WO/2023/020963A1 |
The present invention relates to substituted 1,2,4-thiadiazolyl nicotinamides of the general formula (I), salts or N-oxides thereof, where the radicals in the general formula (I) correspond to the definitions given in the description, an...
|
|
WO/2023/017699A1 |
The present invention addresses the problem of providing: a 3-substituted uracil compound that has excellent germicidal/antimicrobial activity and excellent safety, while being industrially beneficially synthesized; and an agricultural/h...
|
|
WO/2023/018052A1 |
Provided is a tertiary amine derivative, which effectively absorbs a high-energy external light source in a UV region so as to minimize damage to organic materials in an organic electroluminescent device, and thus contributes to a substa...
|
|
WO/2023/016518A1 |
Disclosed are a compound as represented by general formula (I) or a stereoisomer, deuterated compound, solvate, prodrug, metabolite, pharmaceutically acceptable salt or co-crystal thereof and an intermediate thereof; and the use thereof ...
|
|
WO/2023/017452A1 |
The present invention relates to compounds of formula (I). The compounds maybe used to antagonise the Stimulator of Interferon Genes (STING) protein and may thereby treat liver fibrosis, fatty liver disease, non-alcoholic steatohepatitis...
|
|
WO/2023/018747A1 |
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof) used to treat a condition or disease that is associated with hypoxia, or with increased expression of hypoxia-inducible factor HI...
|
|
WO/2023/018155A1 |
The present disclosure provides: a compound of a specific chemical structure, having excellent activity with respect to SHP2 degradation; or a pharmaceutically acceptable salt thereof. The present disclosure also provides a composition c...
|
|
WO/2023/016319A1 |
Provided are a crystal form of Lanifibranor (hereinafter referred to as "compound I"), a preparation method therefor, a pharmaceutical composition containing the crystal form, and a use of the crystal form in the preparation of pan-PPAR ...
|
|
WO/2023/018040A1 |
Provided is a cyano group-substituted carbazole derivative, which effectively absorbs high energy external light source in a UV range so as to minimize damage to organic materials in an organic electroluminescent device, and thus contrib...
|
|
WO/2023/018643A1 |
Provided herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof, useful as RIPK1 inhibitors, and pharmaceutical compositions comprising same. Further provided are methods of use and preparation. (I)
|
|
WO/2023/018781A1 |
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes...
|
|
WO/2023/016525A1 |
An ATR kinase inhibitor as shown in formula I, and a preparation method therefor and the use thereof.
|
|
WO/2023/017451A1 |
The present invention relates to compounds of formula (I). The compounds maybe used to antagonise the Stimulator of Interferon Genes (STING) protein and may thereby treat liver fibrosis, fatty liver disease, non-alcoholic steatohepatitis...
|
|
WO/2023/014861A1 |
Provided are compounds of Formula (I) and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with PPARG.
|
|
WO/2023/011144A1 |
An application of GluN2A and an NMDA receptor containing GluN2A as targets in screening antidepressant drugs, which may achieve rapid and low-cost screening of antidepressant drugs. Specifically, provided is a use of GluN2A, a binding fr...
|
|
WO/2023/015283A1 |
The present disclosure relates to engineered polypeptides comprising degradation domains, compounds, compositions, and methods for their preparation and use as for degrading engineered proteins in cells. The degradation domain comprises ...
|
|
WO/2023/015135A1 |
This disclosure relates to polymorphic forms of N-[4-chloro-2-(pyridin-3-yl)-1,3-thiazol-5-yl]-N-ethyl-3-(me
thylsulfonyl)propanamide, that are useful in the control of pests in the Order Hemiptera, Thysanoptera, Lepidoptera, and the lik...
|
|
WO/2023/011608A1 |
The present application relates to a regulator containing a tricyclic derivative, a preparation method therefor and an application thereof, and in particular to a compound represented by general formula (Ia), a preparation method therefo...
|
|
WO/2023/012044A1 |
A compound of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, which can be used as fungicides.
|
|
WO/2023/014022A1 |
The present invention relates to a pyrimidine derivative, a method for preparing same, and a pharmaceutical composition for preventing or treating cancer comprising same as an active ingredient. The pyrimidine derivative of the present i...
|
|
WO/2023/011656A1 |
A fluorescent dye as represented by formula (I), and a preparation method therefor and the use thereof. The fluorescent dye comprises an electron donor part D, a conjugate system E and an electron acceptor part A. The fluorescent dye wit...
|
|
WO/2023/005875A1 |
Provided is a singlet oxygen-cleavable anti-VEGF prodrug. Provided is a composition comprising a photosensitizer and biocompatible polymer for the co-assembly of photoactivatable nanoparticles with the singlet oxygen-cleavable anti-VEGF ...
|
|
WO/2023/006893A1 |
The present invention relates to compounds that can be used for the prevention, treatment and/or management of pain, in particular chronic pain, such as neuropathic pain, and/or other diseases or disorders that are associated with AT2R a...
|
|
WO/2023/007427A1 |
The present invention disclosed a process for the preparation of phenyl sulfilimines or sulfoximines containing thiazolyl-piperidinyl compounds of formula (I), and intermediates thereof, wherein, R1, R2, Ra, Q, n and m are as defined in ...
|
|
WO/2023/006789A1 |
Compounds of formula I wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides.
|
|
WO/2023/004897A1 |
Provided are a thiadiazole amide compound and the use thereof. The compound has a structural general formula as shown in formula (I), and is a class of compound having an activity in antagonizing an androgen receptor, wherein one of key ...
|
|
WO/2023/008577A1 |
The present invention addresses the problem of providing a Ras/Raf binding inhibitor compound that has the effect of inhibiting Ras/Raf signaling in drug-resistant cancer cells and in a wide range of Ras mutant cancers. A Ras/Raf binding...
|
|
WO/2023/009475A1 |
The present disclosure provides compounds of Formula (I) and (II), which may be R0CK2 inhibitors. The present disclosure also provides pharmaceutical compositions and kits comprising the compounds, and methods of treating or preventing d...
|
|
WO/2023/007429A1 |
The present invention discloses a process for the preparation of phenyl sulfilimines or sulfoximines containing thiazolyl-piperidinyl compounds of formula (I) wherein, R1, R2, Ra, Q, n and m are as defined in the description, and interme...
|
|
WO/2023/004046A1 |
Disclosed herein are compounds that can be used to selectively detect superoxide in samples. Also disclosed herein are compositions comprising the compounds and methods of detecting superoxide using the compounds.
|
|
WO/2023/002443A1 |
The disclosure provides compounds of Formula (I): (I) as further described herein, as well as pharmaceutical compositions comprising such compounds, and methods to use the compounds and pharmaceutical compositions for treatment of certai...
|
|
WO/2023/001299A1 |
The present invention relates to a crystal form of a compounds represented by formula (I), and preparation therefor and an application thereof. Specifically, also disclosed in the present invention are a variety of crystal forms of the c...
|
|
WO/2023/003973A1 |
Disclosed herein are inhibitors of deubiquitinating (DUB) enzyme USP7 (Ubiquitin Specific Protease 7). Also provided are methods of treating a disease or disorder modulated by USP7.
|
|
WO/2023/001794A1 |
There are disclosed certain substituted pyrazine-2-carboxamides of Formula (I), and pharmaceutically acceptable salts thereof, together with compositions containing them and their use in therapy. The compounds are inhibitors of hematopoi...
|
|
WO/2023/285349A1 |
The present invention relates to Carnitine-Palmitoyl-Transferase-1 (CPT-1) inhibitors for use in a method of preventing or treating sepsis in a mammalian subject. The invention also relates to pharmaceutical compositions comprising a Car...
|
|
WO/2023/286719A1 |
The present invention addresses the problem of providing: an industrially advantageous method for producing a uracil compound, which is a production intermediate of a 2,6-dioxo-3,6-dihydropyrimidine compound; and a ureidomethylene compou...
|
|
WO/2021/245083A9 |
The present disclosure relates to heterocyclyl pyridine compounds, processes and intermediates for their preparation as well as the uses thereof for controlling phytopathogenic microorganisms, such as phytopathogenic fungi.
|
